1. Prescribing Information
  2. Important Safety Information
  3. FOR PATIENTS
  4. SIGNUP
  • Prescribing Information
  • Important Safety Information
  • FOR PATIENTS
  • SIGN UP

v-icon

Prescribing Information

Important Safety Information

v-icon

FOR PATIENTS

v-icon

SIGN UP

Logo for Velphoro(R) (sucroferric oxyhydroxide) chewable tablets, the most potent phosphate binder.
Logo for Velphoro(R) (sucroferric oxyhydroxide) chewable tablets, the most potent phosphate binder.
Logo for Velphoro(R) (sucroferric oxyhydroxide) chewable tablets, the most potent phosphate binder.
  1. POTENCY
  2. EFICACY
  3. FLEXIBILITY
  4. TOLERABILITY
  5. ACCESS
  6. RESOURCES
  7. FAQ
  8. For Patients
  9. Privacy Notice
  10. Terms of Use
  11. Notice of Privacy Practices
  12. Prescribing Information
  13. Contact Us
  14. Site Map
  • POTENCY
  • EFFICACY
  • FLEXIBILITY
  • TOLERABILITY
  • ACCESS
  • RESOURCES
  • CLINICAL CARE TEAM
  • For Patients
  • Privacy Notice
  • Terms of Use
  • Notice of Privacy Practices
  • Prescribing Information
  • Contact Us
  • Site Map
v-icon

POTENCY

v-icon

EFFICACY

v-icon

FLEXIBILITY

v-icon

TOLERABILITY

v-icon

ACCESS

v-icon

RESOURCES

v-icon

CLINICAL CARE TEAM

v-icon

For Patients

v-icon

Privacy Notice

v-icon

Terms of Use

v-icon

Notice of Privacy Practices

v-icon

Prescribing Information

v-icon

Contact Us

v-icon

Site Map

Velphoro Health Care Professionals Sitemap

  • Home
  • Potency
  • Efficacy
  • Flexibility
  • Tolerability
  • Access
  • Resources
  • Clinical Care Team
  • Register for Information

INDICATION

Velphoro® (sucroferric oxyhydroxide) is a phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis.

IMPORTANT SAFETY INFORMATION

  • Velphoro chewable tablets must be administered with meals. Velphoro should be chewed or crushed. Do not swallow whole.
  • Patients with peritonitis during peritoneal dialysis, significant gastric or hepatic disorders, following major gastrointestinal (GI) surgery, or with a history of hemochromatosis or other diseases with iron accumulation have not been included in clinical studies with Velphoro. Monitor effect and iron homeostasis in such patients.
  • In a parallel design, fixed-dose study of 6 weeks duration, the most common adverse drug reactions to Velphoro chewable tablets in hemodialysis patients included discolored feces (12%) and diarrhea (6%).
  • Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMG-CoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. For oral medications where a reduction of bioavailability would be clinically significant consider separating of the timing of administration. Consider monitoring clinical responses or blood levels of the concomitant medications.

Velphoro is available by prescription only. For additional important safety information, please see the full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Medical Care North America at 1-800-323-5188 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

This information is intended for use by US healthcare professionals only.

Distributed by:
Fresenius Medical Care North America
Waltham, MA 02451

Fresenius Medical Care Renal Pharmaceuticals
Fresenius Medical Care Renal Pharmaceuticals
Fresenius Medical Care Renal Pharmaceuticals
  1. PRIVACY NOTICE
  2. TERMS OF USE
  3. NOTICE OF PRIVACY PRACTICES
  4. PRESCRIBING INFORMATION
  5. CONTACT US
  6. SITEMAP
  • PRIVACY NOTICE
  • TERMS OF USE
  • NOTICE OF PRIVACY PRACTICES
  • PRESCRIBING INFORMATION
  • CONTACT US
  • SITEMAP
v-icon

PRIVACY NOTICE

v-icon

TERMS OF USE

v-icon

NOTICE OF PRIVACY PRACTICES

v-icon

PRESCRIBING INFORMATION

v-icon

CONTACT US

v-icon

SITEMAP

© 2021 Fresenius Medical Care North America. All Rights Reserved. Fresenius Medical Care and the triangle logo are trademarks of Fresenius Medical Care Holdings, Inc. or its affiliated companies. Velphoro is a registered trademark of Vifor Fresenius Medical Care Renal Pharma Ltd. All other trademarks are the property of their respective owners. Customer Service: 1-800-323-5188.

Do Not Sell or Share My Personal Data • Limit the Use of My Sensitive Personal Information

close-icon
close-icon